{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:35:27Z","timestamp":1791326127208,"version":"4.3.1"},"reference-count":20,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,6,23]],"date-time":"2016-06-23T00:00:00Z","timestamp":1466640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies have identified non-adherence as one of the major contributing factors to treatment failure in chronic myelogenous leukemia (CML) patients receiving imatinib. Published literature has demonstrated a unique role of oncology pharmacists, as part of a multidisciplinary team, in contributing to overall positive outcomes for patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study objective<\/jats:title>\n                    <jats:p>To evaluate the impact of an oncology pharmacist-managed oral anticancer therapy program on oral medication adherence in CML patients versus usual care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Electronic refill history and medical records of patients diagnosed with CML treated with oral tyrosine kinase inhibitors (TKIs) managed by oncology pharmacists during a 6-year period, were retrospectively reviewed. Imatinib adherence rate, as the primary endpoint, was compared with the rate for those in the usual care group within the same organization. The secondary endpoints were descriptive to characterize pharmacist interventions for all TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 56 patients including 45 who were treated with imatinib, were evaluated. The group managed by oncology pharmacists resulted in a higher percentage of imatinib adherence rate compared to usual care (88.6% vs 65.8%, p\u2009=\u20090.0046). A total of 3432 pharmacist encounters were reviewed, and 567 interventions of six categories including side effect monitoring\/management (n\u2009=\u200995; 16.8%); drug interaction detection (n\u2009=\u2009109; 19.2%); TKI dose adjustment (n\u2009=\u200982; 14.5%); laboratory monitoring (n\u2009=\u2009200; 35.3%); non-CML related drug choice (n\u2009=\u200974; 13.1%); and copay assistance (n\u2009=\u20097; 1.2%), were documented. This resulted in a mean of 10.1 interventions per patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our oncology pharmacist-managed oral anticancer therapy program significantly improved TKI adherence rates in CML patients. We attribute the success of our program to consistent follow-up by utilizing routine phone, and secure email follow-ups, that allowed our oncology pharmacists to build a close and trustworthy relationship with patients and families.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155215608523","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T20:21:21Z","timestamp":1443558081000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":85,"title":["Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia"],"prefix":"10.1177","volume":"22","author":[{"given":"Masha SH","family":"Lam","sequence":"first","affiliation":[{"name":"Hematology Oncology Infusion Clinic, Kaiser Permanente Health Plan, Antioch, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Cheung","sequence":"additional","affiliation":[{"name":"Hematology Oncology Infusion Clinic, Kaiser Permanente Health Plan, Antioch, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,6,23]]},"reference":[{"key":"bibr1-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"bibr2-1078155215608523","doi-asserted-by":"crossref","unstructured":"Deininger M, O'Brien SG, Guilhot F,\n                      et\u00a0al.\n                      International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. In:\n                      51st annual meeting of American society of hematolog\n                      , New Orleans, LA, USA, 5\u20138 December 2009. Vol. 114. No. 22. Abstract 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"bibr3-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"bibr4-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"bibr5-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"bibr6-1078155215608523","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"bibr7-1078155215608523","first-page":"174","volume":"35","author":"Dos RSR","year":"2013","journal-title":"Rev Bras Hematol"},{"key":"bibr8-1078155215608523","first-page":"1","volume":"32","author":"Boyle D","year":"2007","journal-title":"US Pharm"},{"key":"bibr9-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2013.001257"},{"key":"bibr10-1078155215608523","doi-asserted-by":"publisher","DOI":"10.2147\/IPRP.S40428"},{"key":"bibr11-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H162"},{"key":"bibr12-1078155215608523","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130278"},{"key":"bibr13-1078155215608523","unstructured":"Campbell C. Outcomes of chronic myelogenous leukemia and adherence to imatinib therapy (CML-AIT) study. Abstract #60; platform category A2. In:\n                      32nd annual meeting of the western state residency conference\n                      , Monterey Bay, California 22\u201325 May, 2012."},{"key":"bibr14-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"bibr15-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"bibr16-1078155215608523","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-11-201212040-00538"},{"key":"bibr17-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.447-453"},{"key":"bibr18-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"bibr19-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9123"},{"key":"bibr20-1078155215608523","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.9334"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215608523","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215608523","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215608523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:27Z","timestamp":1777688187000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215608523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,23]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1177\/1078155215608523"],"URL":"https:\/\/doi.org\/10.1177\/1078155215608523","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,23]]}}}